Postimmunization activity of oligoadenylate synthetase in peripheral blood lymphocytes from healthy individuals. 1989

V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
Department of Clinical Chemistry, Odense University Hospital, Denmark.

The effect of immunizing healthy individuals with either tetanus toxoid or yellow fever live attenuated vaccine was examined by measuring interferon (IFN)-dependent oligoadenylate synthetase (2-5A) activity. This enzyme converts ATP into oligonucleotides coupled together in 2'-5'diester bonds. The synthetized products possess among other effects growth inhibiting properties and stimulate a latent RNase, thus playing an important role in the defense against viral infections. Although 2-5A activity is known to increase following virus infections and perhaps therefore to reflect a previous IFN exposure, little is known about the ability of vaccines to activate 2-5A in healthy individuals. Controlled dosages of commercially available vaccine preparations were therefore administered to 17 healthy Danish volunteers. In one study, the effect of a primary stimulus, yellow fever, was tested. It was found that the 2-5A activity increased to reach a peak by 1,000% by day nine. In another study, the effect of a secondary stimulus or booster, Tetanus toxoid, was tested. The response to this antigen was a 40% decrease in 2-5A activity from day 1 to day 18. Thus, the 2-5A activity highly reflects the type of antigen used for immunization and possibly even whether the individuals previously had been exposed to the given antigen. As IFNs are very shortlived in vivo measuring 2-5A activity is a sensitive way of estimating changes in blood immune cells to exogenous antigens.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013745 Tetanus Toxoid Tetanus Vaccine,Toxoid, Tetanus,Vaccine, Tetanus
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
December 1979, The Journal of biological chemistry,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
April 2009, Genetics and molecular biology,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
February 1987, Journal of interferon research,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
June 1989, Gastroenterologia Japonica,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
May 1986, Nippon Ganka Gakkai zasshi,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
December 1986, Journal of biological response modifiers,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
January 1983, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
November 1992, Clinical immunology and immunopathology,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
January 2008, Anticancer research,
V Bonnevie-Nielsen, and I Heron, and T Kristensen, and B Michelsen, and A Lernmark
June 1988, Gastroenterologia Japonica,
Copied contents to your clipboard!